ACE and metabolic syndrome: Specifically, as compared with controls, they were more likely younger females with higher body mass index; they had an higher Charlson scores; also, they reported a more prevalent use of ACE-inhibitors and beta-blockers; they showed lower hemoglobin levels; eventually, participants with MetS reported a lower PSQI score, as compared with controls.